5402222026-04-012026-06-305402222026-04-012026-06-30in-capmkt:OtherExpenses1Member5402222026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares540222LAURUSLABSNOTLISTEDINE947Q01028LAURUS LABS LIMITEDMain BoardEquity2026-04-012027-03-312026-07-242026-07-09INRCroresQuarterlyFirst quarterSingle segmentManufacturer of Generics API, Generics FDF, Synthesis and Bio Technology2026-07-2414:00:002026-07-2414:42:00Not applicablefalsefalseNo default by the Company.2026-04-012026-06-30UnauditedStandalone17571600000200700000177723000007775100000351200000-94550000021600000003520000009576000003240200000138906000003881700000038817000001032500000-504000009821000000289960000000002899600000-181000002881500000108050000025.375.36005.375.361.The above standalone unaudited financial results of Laurus Labs Limited has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on July 24 2026. The statutory auditors of the Company have carried out a limited review on standalone financial results and have issued an unmodified conclusion in respect of the limited review for the quarter ended June 30 2026. <br /> 2.These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India. <br /> 3.The Company is engaged in the manufacture and sale of Pharmaceuticals which constitutes a single reportable business segment as per Ind AS 108 Operating Segments. <br /> 4.The Board of Directors of the Company in its meeting held on August 21 2025 approved the proposed Composite Scheme of Arrangement for the demerger of Identified Business Undertaking of Laurus Synthesis Private Limited into Sriam Labs Private Limited and amalgamation of Remaining Undertaking of Laurus Synthesis Private Limited with the Company subject to the necessary approval from National Company Law Tribunal Amaravathi under section 230 and 232 of the Companies Act 2013 and other applicable provisions of the Act and the rules made thereunder. The Company have filed the Scheme with the Honble National Company Law Tribunal Amaravati Bench at Amaravati Andhra Pradesh and accordingly the implementation of the Scheme is subject to the final approvals and sanctions of the applicable authorities. Upon approval of the Scheme Laurus Synthesis Private Limited shall stand dissolved without winding up with the Appointed Date of April 01 2026 or such other date as the NCLT may approve. Pending such approval the financial results of the Company are presented without giving effect to the said merger. <br /> 5.During the quarter ended June 30 2026 the Company allotted 393001 equity shares of INR 2 each consequent to the exercise of the stock options by the employees of the Company under the Employee Stock Option Scheme. <br /> 6.The figures for the quarter ended March 31 2026 are the balancing figures between the audited figures in respect of the full financial year ended March 31 2026 and published year to date figures up to third quarter of the financial year ended March 31 2026 which were subject to limited review by the statutory auditors. Other Exxpenses3240200000Remeasurement gains/(losses) on defined benefit plans-24200000-24200000-61000000-18100000